CLN6 抗体 (C-Term)
-
- 抗原 See all CLN6 抗体
- CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))
-
抗原表位
- C-Term
-
适用
- 人, 小鼠, 大鼠, 犬
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This CLN6 antibody is un-conjugated
-
应用范围
- Western Blotting (WB)
- 特异性
- CLN6 antibody was raised against the C terminal of CLN6
- 纯化方法
- Affinity purified
- 免疫原
- CLN6 antibody was raised using the C terminal of CLN6 corresponding to a region with amino acids RLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPWA
- Top Product
- Discover our top product CLN6 Primary Antibody
-
-
- 应用备注
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. - 说明
-
CLN6 Blocking Peptide, catalog no. 33R-8022, is also available for use as a blocking control in assays to test for specificity of this CLN6 antibody
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CLN6 antibody in PBS
- 浓度
- Lot specific
- 缓冲液
- PBS
- 注意事项
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. - 储存条件
- 4 °C/-20 °C
- 储存方法
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
- 抗原
- CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))
- 别名
- CLN6 (CLN6 产品)
- 背景
- CLN6 is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely CLN6 involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.
- 分子量
- 36 kDa (MW of target protein)
- 途径
- Glycosaminoglycan Metabolic Process
-